ReviewCureus2026
Composite Meshes: A Comprehensive Review of Materials, Biomechanics, Clinical Outcomes, and Emerging Innovations.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hernia repair is among the most frequently performed surgical procedures worldwide. Composite meshes, that is, prostheses incorporating at least two distinct functional layers, were developed to reconcile the competing demands of structural durability and peritoneal biocompatibility. This narrative review synthesizes evidence from peer-reviewed research articles, physicomechanical evaluation studies, and clinical outcome data identified through PubMed, MEDLINE, and Scopus searches spanning 2000-2025. Composite meshes are broadly classified by barrier type as either absorbable or permanent (nonabsorbable). Key physicochemical parameters, namely, pore size, filament diameter, mesh weight, suture retention strength, tear resistance, and anisotropy, significantly influence host tissue integration and clinical performance. Absorbable barrier meshes, including C-QUR (Atrium Medical Corporation, Hudson, New Hampshire, United States), PROCEED (Ethicon, Inc. (a Johnson & Johnson company), Somerville, New Jersey, United States), Parietex Composite (Sofradim Production SAS (a Medtronic company), Trévoux, France), and Bard Sepramesh IP Composite (Davol Inc. (a subsidiary of C.R. Bard, Inc., now Becton, Dickinson and Company), Warwick, Rhode Island, United States), facilitate eventual tissue incorporation after barrier degradation within 30-120 days. Permanent barrier meshes, including DUALMESH (W.L. Gore & Associates, Inc., Flagstaff, Arizona, United States) and Bard Composix E/X and L/P (Davol Inc. (a subsidiary of C.R. Bard, Inc., now Becton, Dickinson and Company), Warwick, Rhode Island, United States), provide durable adhesion resistance through an intact expanded polytetrafluoroethylene surface. Clinically, composite meshes demonstrate recurrence rates comparable to conventional polypropylene with measurably reduced adhesion formation in the intraperitoneal position. Complications, including chronic pain, seroma formation, mesh shrinkage, infection, and rare visceral erosion, remain pertinent concerns. Future innovations, including drug-eluting coatings, auxetic mesh geometries, patient-specific three-dimensional printing, and biodegradable biosynthetic scaffolds, hold considerable promise in further optimizing surgical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.